These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29616325)

  • 21. EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.
    Benza R; Corris P; Ghofrani A; Kanwar MK; McLaughlin VV; Raina A; Simonneau G
    Pulm Circ; 2019 Feb; 10(1):2045894019837849. PubMed ID: 30803329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factor Profiles Achieved with Medical Therapy in Prevalent Patients with Pulmonary Arterial and Distal Chronic Thromboembolic Pulmonary Hypertension.
    Bartenstein P; Saxer S; Appenzeller P; Lichtblau M; Schwarz EI; Ulrich S
    Respiration; 2018; 96(2):127-137. PubMed ID: 29642071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Ahn R; Prasad V
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):637. PubMed ID: 30276760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
    Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
    Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
    Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
    Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Riociguat as a treatment regime for pulmonary arterial hypertension: a review.
    Narang BK; Roy S; Sharma R; Singh V; Rawal RK
    Clin Exp Hypertens; 2015; 37(4):323-31. PubMed ID: 25268409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic Evaluation of Riociguat in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension].
    Avxent'eva MV; Cherniavskiĭ AM; Piadushkina EA
    Kardiologiia; 2015; 55(3):33-40. PubMed ID: 26320288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.
    Charalampopoulos A; Gibbs JS; Davies RJ; Gin-Sing W; Murphy K; Sheares KK; Pepke-Zaba J; Jenkins DP; Howard LS
    J Appl Physiol (1985); 2016 Sep; 121(3):623-8. PubMed ID: 27418685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
    Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correction to: Don't Drive Blind: Driving Pressure to Optimize Ventilator Management in ECMO.
    Gupta E; Awsare B; Hirose H; Cavarocchi N; Baram M
    Lung; 2020 Oct; 198(5):793. PubMed ID: 32816113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
    Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
    Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Differences in hemodynamics of thromboembolic and primary pulmonary hypertension].
    Polanowski T; Kurzyna M; Kuca P; Tomkowski W; Fijałkowska A; Kober J; Torbicki A
    Pol Arch Med Wewn; 2000 Nov; 104(5):741-5. PubMed ID: 11434085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction to: Black-White Differences in Willingness to Participate and Perceptions About Health Research: Results from the Population-Based HealthStreet Study.
    Webb FJ; Khubchandani J; Striley CW; Cottler LB
    J Immigr Minor Health; 2019 Apr; 21(2):306. PubMed ID: 29744623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and Economic Analysis Riotsiguata in Patients With Unresectable or Residual Chronic Thromboembolic Pulmonary Hypertension].
    Avksentyev M V; Chernyavskiy A M; Pyadushkin E A
    Kardiologiia; 2015 Mar; 55(3):33-40. PubMed ID: 28294841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Operability assessment in CTEPH: Lessons from the CHEST-1 study.
    Jenkins DP; Biederman A; D'Armini AM; Dartevelle PG; Gan HL; Klepetko W; Lindner J; Mayer E; Madani MM
    J Thorac Cardiovasc Surg; 2016 Sep; 152(3):669-674.e3. PubMed ID: 27083940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.